Jan 02nd 2013 - Edison Investment Research today published a report on Imperial Innovations (IVO.L, LSE:IVO, LON:IVO) entitled "BioMimics 3D: License Or Market?". In summary, the report says:
Imperial Innovations’ third-largest portfolio company, Veryan Medical, has gained a CE mark for its BioMimics 3D peripheral stent. In the Phase II MIMICS study, the stent achieved its primary 30-day safety endpoint with six month clinical data. MIMICS will have full 12-month data by mid-2013, excellent partial 12-month data has been reported. Strategically, Veryan and its investors can use the CE mark to increase the value of the business and potentially realise gains. The CE mark gives access to 60% of the $1bn peripheral stent market. An FDA approval needs Phase III clinical trials.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »